Trammell, S. A. J. et al. Nicotinamide riboside is uniquely and orally bioavailable in mammals. Nat. Commun. 7, 12948 (2016).

Martens, C. R. et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat. Commun. 9, 1286 (2018).

Dollerup, O. L. et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am. J. Clin. Nutr. 108, 343–353 (2018).

Berven, H. et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease. Nat. Commun. 14, 7793 (2023).

Damgaard, M. V. & Treebak, J. T. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci. Adv. 9, eadi4862 (2023).

Orr, M. E. et al. Nicotinamide riboside for mild cognitive impairment: a randomized, placebo-controlled pilot trial. Alzheimers Dement. (Transl. Res. Clin. Interv.) 9, e12378 (2023).

Wu, C.-Y. et al. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long COVID: a randomized controlled trial. EClinicalMedicine 72, 102195 (2025).